A multicenter, retrospective study of accelerated venetoclax ramp‐up in patients with relapsed/refractory chronic lymphocytic leukemia
Matthew S. Davids(Dana-Farber Cancer Institute), Nicole Lamanna(Memorial Sloan Kettering Cancer Center), Mazyar Shadman(University of Washington), Chaitra S. Ujjani(Fred Hutch Cancer Center), Feng Dai(Yale University), Jennifer L. Crombie(Dana-Farber Cancer Institute), Sameer A. Parikh(Mayo Clinic), Dingfeng Jiang(AbbVie (United States)), Cynthia Llamas(AbbVie (United States))
Cited by 6
Related Papers
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k
Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
|Journal of Clinical Oncology|2017|752
Small molecules, big impact: 20 years of targeted therapy in oncology
|The Lancet|2020|606